about
Polymeric immunoglobulin receptor expression is correlated with poor prognosis in patients with osteosarcoma.B7-H3 is overexpressed in patients suffering osteosarcoma and associated with tumor aggressiveness and metastasis.Pirarubicin-based chemotherapy displayed better clinical outcomes and lower toxicity than did doxorubicin-based chemotherapy in the treatment of non-metastatic extremity osteosarcoma.The enhancing effect of a laser photochemotherapy with cisplatin or zolendronic acid in primary human osteoblasts and osteosarcoma cells in vitro.B7-H3 protein expression in a murine model of osteosarcoma.Hypoxia-induced autophagy as an additional mechanism in human osteosarcoma radioresistanceA systematic review of vascular endothelial growth factor expression as a biomarker of prognosis in patients with osteosarcoma.The prognostic value of elevated ezrin in patients with osteosarcoma.Olaratumab for advanced soft tissue sarcoma.Drugs in early clinical development for the treatment of osteosarcoma.Palliative embolization for osteosarcoma.Palliative embolisation for advanced bone sarcomas.Hyperuricemia has an adverse impact on the prognosis of patients with osteosarcoma.Targeting LncRNA-MALAT1 suppresses the progression of osteosarcoma by altering the expression and localization of β-catenin.Simulating thermal effects of MR-guided focused ultrasound in cortical bone and its surrounding tissue.Current and future therapeutic approaches for osteosarcoma.Methotrexate Free Chemotherapy and Limb Salvage Surgery for Paediatric Osteosarcoma in India.Serum C-reactive protein and overall survival of patients with osteosarcoma.
P2860
Q33747680-2C27AAEA-1390-4E85-BCFF-C9F7047577CFQ34935785-D104AC6D-7CC0-4E80-90A0-A48BD3648F6BQ34991299-29DF401E-59D7-4B65-8B62-58011543E994Q36001329-A6E12FAA-081C-4116-9447-D02C480430E2Q37001496-7D8612C8-1111-417C-8313-36F41F6FE2DEQ37005088-C8473143-2525-4E48-B04D-9923D81F7C47Q38099265-FE875343-F255-4264-8F9A-F4BFF289143AQ38135314-0D45E999-0C6B-470B-A9E1-A492141BD236Q38377472-40AB4A89-F7D1-4F9D-A180-BA22DA1CE16EQ38955517-D5581AB3-C5BA-44F8-8E65-6C911E1C5DD5Q39220218-4A6B0F4F-04B6-41C9-9C18-55CBA89C6CE1Q39243816-C988D973-742F-4D75-A5F5-A89BFBCC3183Q40634556-75785513-0E54-4FDB-9B63-CD29CED6DA16Q47162683-F9952204-0A60-4AF6-B6DA-5015BBD7103CQ47296239-850BC591-8AB1-4682-B515-A0CAA4C99260Q47360357-A91F0F74-7864-4004-9D96-5825F8DDF17DQ49189268-3B0C43A5-9010-4EF2-AA27-BDBB8B7D94FBQ53502320-6B90C40F-76B9-409C-B4BC-551A96BF2617
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Palliative therapy for osteosarcoma.
@en
Palliative therapy for osteosarcoma.
@nl
type
label
Palliative therapy for osteosarcoma.
@en
Palliative therapy for osteosarcoma.
@nl
prefLabel
Palliative therapy for osteosarcoma.
@en
Palliative therapy for osteosarcoma.
@nl
P2093
P2860
P50
P356
P1476
Palliative therapy for osteosarcoma
@en
P2093
Alessio Biazzo
Angelo Toscano
Eugenio Rimondi
Gaetano Bacci
Giuseppe Rossi
Marco Alberghini
Mario Mercuri
Nikolin Alì
P2860
P304
P356
10.1586/ERA.10.172
P577
2011-02-01T00:00:00Z